Chronic Hepatitis C
Conditions
Interventions
Case series:bicyclol
Sponsors
The Second Hospital of Nanjing
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-65 years (including 18 and 65), no gender limitation; 2. Hepatitis c virus infection= 6 months; or liver biopsy is consistent with the pathological characteristics of chronic hepatitis c virus in the first 24 months before selection; or chronic hepatitis c is diagnosed according to epidemiological history; 3. Anti-HCV positive; 4. HCV RNA in serum=2000IU/mL; 5. HCV genotype is genotype 1; 6. Patients who sign the consent form voluntarily.
Exclusion criteria
Exclusion criteria: (1) Patients whose chronic hepatitis C virus genotypes are non-type 1; (2) Patients with liver cirrhosis loss, including but not limited to ascites, hepatic encephalopathy and gastrointestinal hemorrhage; (3) There was or is chronic liver disease not caused by HCV (such as: hemochromatosis, autoimmune hepatitis, Wilson's disease, a1-antitrypsin deficiency, drug induced liver disease, etc.); (4) People who have a history of hepatocellular carcinoma and are found suspected hepatocellular carcinoma before or after screening, for example: imaging tests revealed suspicious nodules, or AFP>100ug/L; (5) Patients with positive anti-HAV, or HBsAg, or anti-HIV; (6) Patients whose BMI<18 or =36 kg/m2; (7) Patients who received systematic anti- HCV treatment (such as IFN, RBV and DAA treatment ) in the first three months before being selected; (8) Patients who have or had a mental illness of nervous system and/or mental system, and have poor self-control and cannot express their will; (9) People who are allergic to bicyclol, or with a history of allergy to a variety of drugs, or with a history of specific reactions; (10) Women of childbearing age who are in pregnancy and lactation period and are unwilling to adopt reliable non-hormonal contraceptive measures; (11) Men whose female partners has fertility and is reluctant to take reliablecontraception measures; (12) Patients who affect the evaluation of the test results because of drinking excessively, abusing drugs and substance chronicly; (13) Patients who participated in other clinical trials in the first 3 months before being selected; (14) Except for the above, patients who are not qualified to participate in the clinical trial according to the judgments of researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HCV RNA examination;HCV RNA examination;liver function; | — |
Contacts
Public Contactyangyongfeng
The Second Hospital of Nanjing
Outcome results
None listed